BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Prognosis
16 results:

  • 1. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
    Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
    [No Abstract]    [Full Text] [Related]  

  • 2. Identification of Differentially Methylated Genes Associated with Clear Cell Renal Cell Carcinoma and Their Prognostic Values.
    Wan B; Yang Y; Zhang Z
    J Environ Public Health; 2023; 2023():8405945. PubMed ID: 36793506
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma.
    Xu C; Zeng H; Fan J; Huang W; Yu X; Li S; Wang F; Long X
    BMC Cancer; 2022 Mar; 22(1):264. PubMed ID: 35279104
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. PIWI-Interacting RNA Pathway Genes: Potential Biomarkers for Clear Cell Renal Cell Carcinoma.
    Heng B; Xie X; Zeng W; Li H; Shi L; Ye W; Wu F
    Dis Markers; 2022; 2022():3480377. PubMed ID: 35273654
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response.
    Tian X; Xu WH; Xu FJ; Li H; Anwaier A; Wang HK; Wan FN; Zhu Y; Cao DL; Zhu YP; Shi GH; Qu YY; Zhang HL; Ye DW
    Ann Med; 2022 Dec; 54(1):211-226. PubMed ID: 35037540
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. bub1b Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
    Sekino Y; Han X; Kobayashi G; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
    Oncology; 2021; 99(4):240-250. PubMed ID: 33588420
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]    [Full Text] [Related]  

  • 8. Identification of HIPK3 as a potential biomarker and an inhibitor of clear cell renal cell carcinoma.
    Xiao W; Wang T; Ye Y; Wang X; Chen B; Xing J; Yang H; Zhang X
    Aging (Albany NY); 2021 Jan; 13(3):3536-3553. PubMed ID: 33495417
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The critical impact of tumor size in predicting cancer special survival for T3aM0M0 renal cell carcinoma: A proposal of an alternative T3aN0M0 stage.
    Li L; Shi L; Zhang J; Fan Y; Li Q
    Cancer Med; 2021 Jan; 10(2):605-614. PubMed ID: 33280246
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.
    Zheng W; Zhu W; Yu S; Li K; Ding Y; Wu Q; Tang Q; Zhao Q; Lu C; Guo C
    BMC Cancer; 2020 Nov; 20(1):1066. PubMed ID: 33148204
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Preintervention risk stratification of renal pelvic cancer and ureteral cancer should differ.
    Yang T; Zhang N; Yang B; He D; Fan J; Fan J
    Investig Clin Urol; 2020 Jul; 61(4):397-404. PubMed ID: 32665996
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Identification of Four Pathological Stage-Relevant Genes in Association with Progression and prognosis in Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis.
    Xu D; Xu Y; Lv Y; Wu F; Liu Y; Zhu M; Chen D; Bai B
    Biomed Res Int; 2020; 2020():2137319. PubMed ID: 32309427
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
    Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
    Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.
    Sun M; Tong P; Kong W; Dong B; Huang Y; Park IY; Zhou L; Liu XD; Ding Z; Zhang X; Bai S; German P; Powell R; Wang Q; Tong X; Tannir NM; Matin SF; Rathmell WK; Fuller GN; McCutcheon IE; Walker CL; Wang J; Jonasch E
    Cancer Res; 2017 Oct; 77(19):5313-5326. PubMed ID: 28807937
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Extensively cystic renal neoplasms in adults (Bosniak classification II or III)--possible "common" histological diagnoses: multilocular cystic renal cell carcinoma, cystic nephroma, and mixed epithelial and stromal tumor of the kidney.
    Hora M; Hes O; Michal M; Boudová L; Chudácek Z; Kreuzberg B; Klecka J
    Int Urol Nephrol; 2005; 37(4):743-50. PubMed ID: 16362592
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Survival of Danish cancer patients 1943-1987. Urinary tract.
    Tjønneland A; Skov T; Mellemgaard A
    APMIS Suppl; 1993; 33():137-48. PubMed ID: 8512736
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.